Development and Validation of a Multi-Mineral Fluoride Mouthrinse
Primary Purpose
Dental Caries
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Fluoride
Fluoride
Sponsored by
About this trial
This is an interventional prevention trial for Dental Caries focused on measuring remineraliation, pre-existing white-spot (non-cavitated) enamel lesions
Eligibility Criteria
Inclusion Criteria:
To participate in this study, panelists will be required to meet the following criteria:
- Subjects must be 13 - 65 years of age;
- Subjects must read and sign the Informed Consent prior to initiation of study procedures. All subjects will receive a copy of the signed Informed Consent;
- Subjects must have a reasonable functional dentition, without a large number of missing teeth, and teeth #'s 22-27 present;
- Have normal salivary gland function (unstimulated whole salivary flow rate equal to or greater than 0.25 ml/min and paraffin stimulated whole salivary flow rate equal to or at least 1.0 ml/min);
- Subjects must be willing to participate in the study, be able to follow the study directions, be willing to return for all specified visits at their appointed time, and to use the product as per instructions;
- Subjects must be in good general health based on medical history and oral soft and hard tissue examination.
Exclusion Criteria:
Criteria that will not permit participation in this study will be as follows:
- Any subject who is pregnant or lactating - based on oral interview only - as pregnancy may interfere with the outcome of the study;
- Any subject who has a systemic health condition such as diabetes that could affect the outcome of the study at the discretion of the examiner;
- Any subject who has an oral condition, such as excessive, untreated dental caries, periodontal disease, chronic dental neglect, or any oral pathology including xerostomia determined by oral examination and subject history that in the opinion of the dental examiner could affect the outcome of the study;
- Any subject who has full dentures, or full orthodontic appliances. No use of nightguards will be permitted during the study period;
- Any subject who uses oral care products (other than those permitted) during the treatment or wash-out periods;
- Any subject with an immunological disorders such as HIV positive, AIDS, and systemic Lupus Erythematosis;
- Any subject concurrently participating in another clinical study;
- Any subject currently taking antibiotics or other medications, which in the opinion of the Investigator/Examiner might influence the study outcome;
- Any subject with a history of sensitivity to oral products or allergies to ingredients in the products;
- Any subject who fails to keep any of their scheduled appointments.
Sites / Locations
- Crispus Attucks Medical Magnet High School
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
B
A
Arm Description
226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
Outcomes
Primary Outcome Measures
Remineralization of non-cavitated enamel lesions.
Secondary Outcome Measures
Full Information
NCT ID
NCT00642252
First Posted
March 17, 2008
Last Updated
March 23, 2015
Sponsor
Indiana Nanotech, LLC
Collaborators
The University of Texas Health Science Center at San Antonio
1. Study Identification
Unique Protocol Identification Number
NCT00642252
Brief Title
Development and Validation of a Multi-Mineral Fluoride Mouthrinse
Official Title
Development and Validation of a Multi-Mineral Fluoride Mouthrinse
Study Type
Interventional
2. Study Status
Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Indiana Nanotech, LLC
Collaborators
The University of Texas Health Science Center at San Antonio
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The primary goals of this project are to determine the anticaries benefits of a prototype multi-mineral mouthrinse containing 225 ppm fluoride and 30 ppm of a Ca through the remineralization of enamel white-spots (non-cavitated lesions). The selection of patients with pre-existing white-spot lesions will permit an opportunity to evaluate the efficacy of the multi-mineral mouthrinse in reminerzalizing and/or inhibiting progression of enamel white-spot lesions.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dental Caries
Keywords
remineraliation, pre-existing white-spot (non-cavitated) enamel lesions
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)
8. Arms, Groups, and Interventions
Arm Title
B
Arm Type
Experimental
Arm Description
226 ppm fluoride + 30 ppm calcium 'prototype/new' mouthrinse
Arm Title
A
Arm Type
Active Comparator
Arm Description
ADA-accepted over-the-counter 226 ppm fluoride mouthrinse (i.e. ACT, 226 ppm fluoride mouthrinse distributed by Chattem, Inc.)
Intervention Type
Drug
Intervention Name(s)
Fluoride
Other Intervention Name(s)
ACT fluoride mouthrinse
Intervention Description
Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
Intervention Type
Drug
Intervention Name(s)
Fluoride
Other Intervention Name(s)
New mouthrinse
Intervention Description
Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
Primary Outcome Measure Information:
Title
Remineralization of non-cavitated enamel lesions.
Time Frame
baseline, 6, 12, 18, 24 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
13 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
To participate in this study, panelists will be required to meet the following criteria:
Subjects must be 13 - 65 years of age;
Subjects must read and sign the Informed Consent prior to initiation of study procedures. All subjects will receive a copy of the signed Informed Consent;
Subjects must have a reasonable functional dentition, without a large number of missing teeth, and teeth #'s 22-27 present;
Have normal salivary gland function (unstimulated whole salivary flow rate equal to or greater than 0.25 ml/min and paraffin stimulated whole salivary flow rate equal to or at least 1.0 ml/min);
Subjects must be willing to participate in the study, be able to follow the study directions, be willing to return for all specified visits at their appointed time, and to use the product as per instructions;
Subjects must be in good general health based on medical history and oral soft and hard tissue examination.
Exclusion Criteria:
Criteria that will not permit participation in this study will be as follows:
Any subject who is pregnant or lactating - based on oral interview only - as pregnancy may interfere with the outcome of the study;
Any subject who has a systemic health condition such as diabetes that could affect the outcome of the study at the discretion of the examiner;
Any subject who has an oral condition, such as excessive, untreated dental caries, periodontal disease, chronic dental neglect, or any oral pathology including xerostomia determined by oral examination and subject history that in the opinion of the dental examiner could affect the outcome of the study;
Any subject who has full dentures, or full orthodontic appliances. No use of nightguards will be permitted during the study period;
Any subject who uses oral care products (other than those permitted) during the treatment or wash-out periods;
Any subject with an immunological disorders such as HIV positive, AIDS, and systemic Lupus Erythematosis;
Any subject concurrently participating in another clinical study;
Any subject currently taking antibiotics or other medications, which in the opinion of the Investigator/Examiner might influence the study outcome;
Any subject with a history of sensitivity to oral products or allergies to ingredients in the products;
Any subject who fails to keep any of their scheduled appointments.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
George K Stookey, PhD
Organizational Affiliation
Indiana Nanotech
Official's Role
Study Director
Facility Information:
Facility Name
Crispus Attucks Medical Magnet High School
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Development and Validation of a Multi-Mineral Fluoride Mouthrinse
We'll reach out to this number within 24 hrs